Navigation Links
Innocoll Announces Appointment of Anthony H. Wild Ph.D. to Chairman of the Board
Date:6/17/2010

from the University of York where he earned an honors degree in Chemistry.  He also holds a Ph.D. degree in physical chemistry from the University of Cambridge (Churchill College).

Dr. Wild commented, "I am honored to take over from Rolf Schmidt as Chairman and would like to thank him for his vision in founding Innocoll and leading the Board up to this point.  I am very pleased how far the company has come and am excited at our prospects in the coming months and years".

Rolf Schmidt noted, "I have known Dr. Wild for a number of years as a professional with just the skill set to help bring the growing pipeline of the company's products to market. His deep understanding of the industry is a special asset of significant value to the growth of our company. It is a privilege to work with Tony in this exciting period."

About Innocoll, Inc.

Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx® and Liquicoll®. Innocoll has licensed its US marketing rights to its lead product, CollaRx GENTAMICIN SURGICAL IMPLANT to Baxter Healthcare, a division of Baxter International Inc. (NYSE: BAX.) The product is currently in phase 3 development in the US for the prevention of surgical site infections.  It is approved for sale in 49 countries in Europe, Latin America, Middle East, Africa and Asia<
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Innocoll Announces Provisional Findings From Its Three Phase 2 Clinical Trials Investigating CollaRx(R) GENTAMICIN TOPICAL for the Treatment and Prevention of Diabetic Foot Infections
2. Innocoll, Inc. Files 510 (k) Application for CollaRx Lidocaine Sponge
3. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
4. Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors
5. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Innocoll Announces Closing of $30 Million Equity Financing Investment
7. Healthcare Data Solutions Announces New Service, PrescriberPRO Rx
8. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
9. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
10. FASEB Announces Recipient of the 2011 Excellence in Science Award
11. AgFeed Industries, Inc. Announces Stocking Agreement for Xinyu Production Pod
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 21, 2015 Research ... addition of the "Analysis of the Global ... offering. Globally, flow cytometry remains a ... proliferation, cancer, and stem cells. But the market ... because of demand from underdeveloped nations to quantitate ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... July 28, 2015  Moerae Matrix Inc. announced ... clinical trial with MMI-0100, a first-in-class inhibitor of ... for pulmonary disorders characterized by inflammation and fibrosis.  ... Kingdom , is a double-blind, two-way cross-over ... safety and tolerability of MMI-0100 when given via ...
(Date:7/28/2015)... CITY , July 28, 2015 /PRNewswire/ - Aeterna ... today announced that it has granted to German ... funding the development and commercialization of biotechnology (collectively, ... live recombinant oral allogenic tumor vaccine technology (the ... for prostate cancer which is ready to enter ...
Breaking Biology Technology:Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3
... Conn. Two major steps toward putting quantum computers into ... a qubit onto wires and transmitting the signal to a ... team of scientists at Yale. The accomplishments are reported in ... on which it is highlighted as the cover along with ...
... (Nasdaq: PRXL ), a leading global ... of the acquisition,of Taiwan-based APEX International Clinical ... release. In conjunction with the acquisition and ... its forward-looking,financial guidance for the first quarter ...
... 26 Today at the Clinton Global,Initiative ... a,ground-breaking vaccine to eliminate epidemic meningitis in ... developed by the Meningitis,Vaccine Project, a partnership ... produced by Serum Institute of India Limited ...
Cached Biology Technology:Yale scientists make 2 giant steps in advancement of quantum computing 2Yale scientists make 2 giant steps in advancement of quantum computing 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 2PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso 3
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... The US military wants to buy large quantities of anthrax, ... over its commitment to treaties designed to limit the spread ... uncovered that relate to the US army' Dugway Proving ... production of bulk quantities of a non-virulent strain of anthrax, ...
... dominated this week by the continuing debate over HIV/AIDS ... drugs were not the only way to fight HIV/AIDS, ... previously denying links between HIV and AIDS, the South ... year. As many as five million South Africans are ...
... comes to the deadly skin cancer melanoma, studying ... provide insight into the disease's development, according to ... predoctoral fellow at Stanford University School of Medicine. ... melanoma development, scientists have not been able to ...
Cached Biology News:US Army plans to bulk-buy anthrax 2Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance 2Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance 3
... DNA and RNA endonucleolytically to yield ... DNA:RNA or RNA:RNA) are resistant to ... of enzyme (1). The enzyme is ... double-stranded DNA (2), for selective cleavage ...
Miniature FRENCH Pressure Cell with 3.7ml capacity; pressure up to 20,000 psi....
... Labsystems Nepheloskan Ascent is the ... measurement in microplates. Nepheloskan measures ... ultra-sensitive technique for particle quantification. ... solubility testing in drug discovery, ...
... High Vacuum pumps deliver critical performance for ... ballast control optimizes pump performance to suit ... allows for convenient checking of proper oil ... of pumps is designed to work with ...
Biology Products: